Ibrutinib,Rituximab,venetoclax
roche,janssen,abbvie,biogen
['ibru', 'lymsm', 'lymphoma', 'cll']
#eha2022 | peter hillmen presented results from the phase iii ncri flair trial, showing a combination of ibrutinib + ven results in a high rate of mrd negativity in the blood (71.3%) and marrow (65.4%) within 2 years of treatment in untreated cll #lymphoma #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm